Merrimack Pharmaceuticals, Inc. (MACK)
| Market Cap | 69.46M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.89M |
| Shares Out | 13.41M |
| EPS (ttm) | -0.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,750 |
| Open | 5.10 |
| Previous Close | 5.11 |
| Day's Range | 5.00 - 5.20 |
| 52-Week Range | 3.66 - 7.41 |
| Beta | 1.71 |
| Analysts | Sell |
| Price Target | n/a |
| Earnings Date | May 5, 2022 |
About MACK
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Financial Performance
Financial StatementsNews
Merrimack Reports First Quarter 2022 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2022 financial results for the period ended March 31,...
Merrimack Reports Full Year 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2021 Financial Results
Merrimack Reports Third Quarter 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals Reports Third Quarter 2021 Financial Results
Merrimack Reports Second Quarter 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) (“Merrimack” or the “Company”) today announced its second quarter 2021 financial results for the period ended June 30, 20...
Merrimack Reports Full Year 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2020 Financial Results
Merrimack Reports Third Quarter 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals Q3 2020 Earnings Release
Merrimack Reports Second Quarter 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2020 Financial Results